Review immune response of targeting CD39 in cancer
Abstract The ATP-adenosine pathway has emerged as a promising target for cancer therapy, but challenges remain in achieving effective tumor control. Early research focused on blocking the adenosine generating enzyme CD73 and the adenosine receptors A2AR or A2BR in cancer. However, recent studies hav...
Saved in:
Main Authors: | Yao Liu (Author), Zhongliang Li (Author), Xiaoguang Zhao (Author), Jing Xiao (Author), Jiacheng Bi (Author), Xian-Yang Li (Author), Guokai Chen (Author), Ligong Lu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
by: Ana Maria Oliveira Battastini, et al.
Published: (2021) -
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
by: Laura Schäkel, et al.
Published: (2020) -
A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment
by: Zheng Wei, et al.
Published: (2021) -
CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer
by: Yang Shen, et al.
Published: (2024) -
CD39 and immune regulation in a chronic helminth infection: The puzzling case of Mansonella ozzardi.
by: Nathália F Lima, et al.
Published: (2018)